Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vaccination for leukemia.

Jeffrey J Molldrem1

  • 1Transplantation Immunology Section, Blood and Marrow Transplantation Department, University of Texas MD Anderson Cancer Center, Houston, 77030, USA. jmolldrc@mdanderson.org

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|January 10, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human NKT10 cells are enriched in cord-derived invariant natural killer T cells and mediate immune-regulation in a xenogeneic graft-versus-host disease model.

Frontiers in immunology·2026
Same author

Biophysical modeling for accurate T cell specificity prediction of viral and tumor antigens.

Nature communications·2026
Same author

Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.

Blood advances·2026
Same author

2-Methoxyestradiol Treatment Prevents Graft-versus-Host Disease While Preserving Graft-versus-Leukemia Effect in Mice.

bioRxiv : the preprint server for biology·2025
Same author

Copper Sulfide Nanoparticle-Mediated Photothermolysis Induces Immunogenic Cell Death in Ovarian Cancer Cells.

bioRxiv : the preprint server for biology·2025
Same author

Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease.

Blood·2025
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

End of headings.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

ASTCT Notes.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2021
Same journal

Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality?

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2020
Same journal

Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2020
See all related articles

Targeted immunotherapy for myeloid leukemia shows promise. Early clinical trials suggest that leukemia vaccination can stimulate effective T-cell immunity, paving the way for future combination therapies.

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • Myeloid leukemias originate from antigen-presenting cells, making them suitable for immunotherapy.
  • Donor lymphocyte infusions demonstrate existing T-cell immunity against chronic myeloid leukemia.
  • Advances in antigen identification and tumor immunology are crucial for developing leukemia vaccines.

Purpose of the Study:

  • To review T-cell biology relevant to leukemia immunotherapy.
  • To discuss key leukemia-associated antigens.
  • To summarize preliminary results from clinical leukemia vaccine trials.

Main Methods:

  • Review of fundamental T-cell biology.
  • Analysis of identified leukemia-associated antigens.
  • Evaluation of preliminary clinical vaccine trial data for leukemia.

Related Experiment Videos

Main Results:

  • Early clinical trials indicate that leukemia vaccination can elicit an immune response.
  • Evidence suggests that effective anti-leukemia immunity is achievable through vaccination.
  • The findings support the potential of vaccination in leukemia treatment.

Conclusions:

  • Leukemia vaccination is a developing field with promising early results.
  • Further research and clinical trials are needed to optimize leukemia immunotherapy.
  • Vaccination strategies may be integrated into future combined therapeutic approaches for leukemia.